| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 46.605 | 82.660 | 180.673 | 322.410 | 180.491 | 533.390 | 376.059 | 558.101 | - | - |
| Total Income - EUR | 46.634 | 83.674 | 180.781 | 323.008 | 180.719 | 535.952 | 380.012 | 567.529 | - | - |
| Total Expenses - EUR | 84.208 | 157.243 | 158.166 | 202.255 | 165.212 | 344.610 | 222.621 | 321.826 | - | - |
| Gross Profit/Loss - EUR | -37.574 | -73.568 | 22.615 | 120.753 | 15.508 | 191.342 | 157.391 | 245.703 | - | - |
| Net Profit/Loss - EUR | -37.623 | -74.404 | 20.807 | 117.741 | 13.701 | 185.988 | 154.552 | 240.886 | - | - |
| Employees | 5 | 8 | 10 | 8 | 7 | 7 | 5 | 5 | - | - |
Check the financial reports for the company - Revolve Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.160 | 3.006 | 29.704 | 30.805 | 27.181 | 20.881 | 60.403 | 136.860 | - | - |
| Current Assets | 98.009 | 93.733 | 102.554 | 166.409 | 188.223 | 406.854 | 625.945 | 717.119 | - | - |
| Inventories | 66.002 | 39.405 | 46.197 | 8.240 | 15.497 | 48.815 | 31.611 | 40.765 | - | - |
| Receivables | 21.554 | 25.153 | 33.938 | 63.618 | 86.088 | 314.178 | 480.526 | 491.001 | - | - |
| Cash | 10.453 | 29.174 | 22.420 | 94.551 | 86.638 | 43.861 | 113.808 | 185.353 | - | - |
| Shareholders Funds | 5.496 | -69.189 | -47.211 | 71.397 | 83.716 | 268.117 | 416.723 | 584.196 | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | - | - |
| Debts | 93.673 | 165.928 | 179.468 | 125.817 | 131.689 | 159.619 | 269.625 | 269.782 | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Revolve Pharma Srl